Columbus Clinical Services | Miami, FL

Research site

About

Columbus Clinical Services was created in 2005 since then has provide excellent patient care in our community. Our medical center provides comprehensive medical services, clinical trials and Aesthetic Medicine by experienced professionals whose goal is caring for your medical needs at any age.

Location

110 North West 27th Avenue, Miami, Florida, United States of America

Website

https://columbusclinicalservices.net

Site insights

Top conditions

Top treatments

Bococizumab

Mirikizumab

Lansoprazole

Guselkumab

Obicetrapib

Olezarsen

Plecanatide

Vonoprazan

Cariprazine

Bromocriptine mesylate

Data sourced from clinicaltrials.gov

Contact this site

Interested in a Study?

Verified by this site

Active trials

17 of 37 total trials

Locations recently updated

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical resp...

Active, not recruiting

Ulcerative Colitis

Drug: Placebo SC

Drug: Mirikizumab SC

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR)

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting

Ulcerative Colitis

Drug: Guselkumab

Drug: Placebo

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (ASTRO)

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting

Colitis, Ulcerative

Drug: Guselkumab Dose 2

Other: Placebo

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling

Primary Prevention of Atherosclerotic Cardiovascular Disease

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Drug: Placebo in 1.5ml

Locations recently updated

A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling

Severe Hypertriglyceridemia

Drug: Olezarsen

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Active, not recruiting

Severe Hypertriglyceridemia

Drug: Placebo

Drug: Olezarsen

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling

Bipolar I Disorder

Depression

Drug: Placebo

Drug: Cariprazine

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

Enlicitide Decanoate (MK-0616) (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling

Arteriosclerosis

Hypercholesterolaemia

Drug: Enlicitide decanoate

Drug: Placebo

Infant Formula and Toddler Drink Feeding Study

The purpose of this study is to evaluate the growth and development outcomes of infants fed a new infant formula and toddler drink through 24 months...

Active, not recruiting

Growth

Other: Control Toddler Drink

Other: Control Infant Formula

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only

Migraine

Drug: Ubrogepant

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizop...

Enrolling

Bipolar I Disorder

Schizophrenia

Drug: Cariprazine Flexible Dose

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Inhaled Long-Acting Muscarinic Antagonist

Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19

This is a clinical trial to evaluate the safety, PK, viral shedding and clinical effects of Pentarlandir™ UPPTA in patients with early COVID-19. Appr...

Enrolling

Coronavirus Disease 2019

Drug: Pentarlandir™ UPPTA

Drug: Placebo

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholester...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Dyslipidemias

Drug: Placebo

Drug: Obicetrapib

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling

Migraine

Drug: Placebo-Matching Ubrogepant

Drug: Ubrogepant

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

Primary Objective:Primary population (former smokers cohort):* Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of ac...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Itepekimab SAR440340